A bridge over troubled water-Extending induction for high-risk neuroblastoma patients with poor end-of-induction response.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 35665920.
- Also identified by DOI 10.1002/cncr.34267 and PMC identifier 9728546.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A subset of high-risk neuroblastoma patients who have a poor end of Induction response may benefit from receiving chemoimmunotherapy, as bridge therapy, prior to Consolidation. Prospective studies evaluating this therapeutic approach and improved identification of biomarkers of response are warranted.
Medical subject headings
- Neuroblastoma